Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ⅰ/Ⅱ Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Next Previous
Trial Profile

A Phase Ⅰ/Ⅱ Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZG-006 (Primary)
  • Indications Neuroendocrine carcinoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

  • 17 Sep 2024 Trial design published at the 49th European Society for Medical Oncology Congress.
  • 01 Nov 2023 Status changed from not yet recruiting to recruiting.
  • 20 Oct 2023 Planned initiation date changed from 1 Sep 2023 to 1 Nov 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top